Patents by Inventor Marcie A. Glicksman

Marcie A. Glicksman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Inhibiting Tumor Growth
    Publication number: 20120208204
    Abstract: The invention provides methods and compositions for inhibiting p53-inactivated cancers. Cancer cells are preferentially inhibited compared to normal cells by inhibiting tumor survival kinases that are required for growth of tumor cells but not normal cells.
    Type: Application
    Filed: June 3, 2010
    Publication date: August 16, 2012
    Applicants: The Brigham and Women's Hospital, Inc., Peresident and Fellows of Harvard College
    Inventors: Amy Baldwin, Dorre Grueneberg, Ed Harlow, Jun Xian, Karl Munger, Karin Hellner, Marcie Glicksman, Ross Stein, Gregory Cuny
  • Compounds that enhance Atoh1 expression
    Patent number: 8188131
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: May 29, 2012
    Assignees: Massachusetts Eye & Ear Infirmary, Brigham & Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION
    Publication number: 20090232780
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Application
    Filed: February 9, 2009
    Publication date: September 17, 2009
    Applicant: Massachusetts Eye & Ear Infirmary
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Protein kinase inhibitors for treatment of neurological disorders
    Patent number: 5756494
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 26, 1998
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • Protein kinase inhibitors for treatmen of neurological disorders
    Patent number: 5741808
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: April 21, 1998
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • Protein kinase inhibitors for treatment of neurological disorders
    Patent number: 5621101
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 15, 1997
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • K-252a derivatives for treatment of neurological disorders
    Patent number: 5621100
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: April 15, 1997
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • K-252 derivatives which enhance neurotrophin-induced activity
    Patent number: 5516772
    Abstract: Disclosed are derivatives of the indolocarbazole alkaloid K-252a of the Formulae I-VI, useful for enhancing neurotrophin-induced activity of neurotrophin responsive cells. A particularly preferred neurotrophin is NT-3, and a particularly preferred neurotrophin responsive cell is one which comprises a trk receptor. The enhanced neurotrophin-induced activity occasioned by the disclosed K-252a derivatives may be determined by the following assays: ChAT activity; DRG neuronal survival; or cell division (mitogenesis).
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: May 14, 1996
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Marcie A. Glicksman, Robert L. Hudkins, David P. Rotella, Nicola T. Neff, Chikara Murakata
  • K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
    Patent number: 5468872
    Abstract: Functional K-252a derivatives are used to enhance trk phosphorylation and to potentiate the activity of neurotrophin-3 (NT-3). These compounds can be used to treat neurological disorders, alone or in combination with NT-3.
    Type: Grant
    Filed: September 16, 1993
    Date of Patent: November 21, 1995
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Marcie A. Glicksman, David P. Rotella, Nicola Neff, Chikara Murakata
  • Selected protein kinase inhibitors for the treatment of neurological disorders
    Patent number: 5461146
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. Also, a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: October 24, 1995
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman